Cusatuzumab,Abbexa,abx831459
Cusatuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD70/TNFSF7, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Cusatuzumab is an experimental SIMPLE antibody that targets CD70, which is an immune checkpoint target involving hematological malignancies, a variety of solid tumors, and a variety of autoimmune diseases. Cusatuzumab aims to block CD70 by targeting complement-dependent cytotoxicity, enhancing antibody-dependent cell-mediated phagocytosis, and enhancing antibody-dependent cell-mediated cytotoxicity, killing CD70-expressing cancer cells, and recovering Immune monitoring of solid tumors.
Host
Human
Reactivity
Human
Application
ELISA, WB
Conjugate
Unconjugated
Platform ID
BAB106042623
Abbexa
Contact
Tel: +44 (0) 1223 755950
Fax: +44 (0) 1223 755951
Email:
Product Specifications
Specifications
NameCusatuzumab
Cat. No.abx831459
HostHuman
IsotypeIgG1 Lambda
ReactivityHuman
ConjugationUnconjugated
ApplicationELISA, WB
Working DilutionsOptimal dilutions/concentrations should be determined by the end user.
ClonalityMonoclonal
ConcentrationBatch-dependent, typically between 0.5-2.0 mg/ml.
TargetCD70/TNFSF7
PurityPurified from cell culture supernatants by Protein A/G chromatography.
Appearance/FormLiquid
Formulation0.01 M PBS. pH 7.4.
StorageAliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Regulatory StatusResearch Use Only
Category Paths
- Products>Primary Antibodies>Biosimilar Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.